You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Breast cancer

Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer

  • Technology appraisal guidance
  • Reference number: TA214
  • Published:  23 February 2011
  • Guidance
  • Tools and resources
  • Information for the public
  • History
Download guidance (PDF)
  • Overview
  • 1 Recommendations
  • 2 The technology
  • 3 The manufacturer's submission
  • 4 Consideration of the evidence
  • 5 Recommendations for further research
  • 6 Appraisal Committee members, and NICE project team
  • 7 Sources of evidence considered by the Committee

5 Recommendations for further research

5.1

Further research designed to investigate differences in health-related quality of life and the clinical effectiveness of bevacizumab in subgroups, such as those with prior taxane exposure, would be particularly useful.


Next page 6 Appraisal Committee members, and NICE project team Previous page 4 Consideration of the evidence